Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AU-011

Phase 1Small molecule

AAura Biosciences

AU-011 is one of 70 small molecule programs targeting Melanoma. It is currently in Phase 1.

2

Indications

4

Total Trials

2

Active Trials

69

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Bladder CancerActive, not recruiting

MelanomaPreclinical

Active, not recruiting

Bladder CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Tecentriq

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

ABP 234

Fotemustine

Single Dose of

Boehringer Ingelheim

GSK2118436

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Opdualag

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Bladder Cancer

NCT05483868

Q4 2027

Phase 2Recruiting

Metastases

NCT06643884

Clinical

Trials by Indication[1]

Melanoma2 trials

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Terminated·AAura Biosciences··NCT05266430·2 enrolled

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Completed·AAura Biosciences·Phase 2·NCT04417530·22 enrolled

Bladder Cancer1 trial

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Recruiting·AAura Biosciences·Phase 1·NCT05483868·55 enrolled

Metastases1 trial

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Recruiting·AAura Biosciences·Phase 2·NCT06643884·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AU-011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AU-011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AU-011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aura Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAura Biosciences

Related News